Our partner is focused on developing therapies for serious autoimmune and rare diseases. They aim to address unmet medical needs by targeting specific immune pathways, with the goal of improving patient outcomes through more effective and targeted treatments.

This critical hire was responsible for developing and directing the regulatory strategy, objectives, and programs for early- and late-stage drug products, as well as leading the Quality Assurance department, which oversaw all GxP operations.